[拉米夫定联合中药治疗慢性乙型肝炎患者时HBeAg血清学转换时间的评估]
[Evaluation on HBeAg conversion time when treating chronic hepatitis B patients with combination of lamivudine and traditional Chinese medicine].
作者信息
Bai Song-Lin, Hu Xiao-Yu, Zhong Sen
机构信息
The Department of Infection, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
出版信息
Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Dec;29(12):1243-7.
OBJECTIVE
To evaluate the effect of the combined use of traditional Chinese medicine and lamivudine (LMD) in treating chronic hepatitis B patients, and to follow the serological response for six months or longer.
METHODS
CNKI, Wanfang data, VIP data, CBMdisk, MEDLINE, EMBASE, BIOSIS and Cochrane Central Register of Controlled Trials database and literature were searched, to include randomized controlled trails (RCT) that used LMD alone or combined with traditional Chinese medicine. RevMan 4.2 was used for data analysis.
RESULTS
The Meta analysis of 7 trails demonstrated that the HBeAg conversion rate in treatment group was higher than those from the control group, and the differences were statistically significant at 6, 9, 12 months.
CONCLUSION
Data demonstrated that early intervention of traditional Chinese medicine might increase the HBeAg conversion rate but conclusion needs to be more specific to the types of trials.
目的
评估中药与拉米夫定（LMD）联合使用治疗慢性乙型肝炎患者的效果，并对血清学反应进行6个月或更长时间的随访。
方法
检索中国知网、万方数据、维普数据、中国生物医学文献数据库、医学索引数据库、荷兰医学文摘数据库、生物学文摘数据库和考克兰系统评价数据库及相关文献，纳入单独使用LMD或LMD联合中药的随机对照试验（RCT）。采用RevMan 4.2进行数据分析。
结果
7项试验的Meta分析表明，治疗组的HBeAg血清学转换率高于对照组，在6、9、12个月时差异有统计学意义。
结论
数据表明，中药早期干预可能提高HBeAg血清学转换率，但结论需要更具体地针对试验类型。
Zotero 插件